Gemcitabine for Marginal Zone Lymphoma
Gemcitabine for Marginal Zone Lymphoma
Marginal zone lymphoma, one of the indolent lymphoma, is believed to be incurable with
 chemotherapy. Thus the investigators need a novel agent for marginal zone lymphoma.
 Gemcitabine has been tried as one of salvage chemotherapy regimen and has been shown to have
 anti-lymphoma activity. To the investigators' knowledge, there has been no trial of
 gemcitabine for marginal zone lymphoma. Thus the investigators made a plan to investigate the
 role of gemcitabine in marginal zone lymphoma.
We designed a multi-center phase II trial of gemcitabine for advanced stage marginal zone
 B-cell lymphoma. Marginal zone lymphoma needs novel agent to improve clinical course by
 chemotherapy. Recent trials with new agents for indolent lymphoma shows promising results.
 Gemcitabine is known to have activity to non-Hodgkin's lymphoma and has less adverse effects
 than other new agents. With this background gemcitabine will be tried as a single agent for
 advanced marginal zone lymphoma.

 Gemcitabine will be administered with 1,250mg/sq.m on days 1 and 8 every 3 weeks. Response
 will be assessed by IWC criteria.
Inclusion Criteria:

 -  Histologically confirmed marginal zone B-cell lymphoma

 -  Performance status (ECOG) ≤3

 -  Age ≥ 18

 -  At least one or more bidimensionally measurable lesion(s):

 -  2 cm by conventional CT

 -  1 cm by spiral CT

 -  skin lesion (photographs should be taken)

 -  measurable lesion by physical examination

 -  Laboratory values:

 -  Cr < 2.0 mg% or Ccr > 60 ml/min

 -  Transaminase < 3 X upper normal value

 -  Bilirubin < 2 mg%

 -  ANC > 1500/ul, platelet > 75,000/ul

 -  Informed consent

 -  Ann Arbor stage III or IV

 Exclusion Criteria:

 -  Any other malignancies within the past 5 years except skin basal cell ca or CIS of
 cervix

 -  Serious comorbid diseases

 -  Pregnancy or breast feeding